SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 58.00+3.6%Nov 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant10/17/2013 6:51:05 AM
   of 507
 
Nektar Therapeutics reports on advancements with clinical pipeline and introduces new preclinical candidates at Investor and Analyst R&D day
Co will present an overview of the company's proprietary drug candidate pipeline during the company's R&D Day for investors and analysts today from 11:30 a.m. to 4:30 p.m. ET in New York City. Pain management specialists will present data from two Phase 2 studies of NKTR-181, the company's novel mu-opioid analgesic molecule. New topline clinical data will be presented from an ongoing investigator-sponsored Phase 2 study of Nektar's proprietary cancer drug candidate, NKTR-102, in patients with Avastin-resistant high-grade glioma. The company will also present new receptor-based research for NKTR-192, the company's novel analgesic molecule for acute pain, which is currently in Phase 1 development. Also, for the first time, the company will provide details for two new drug candidates including a peripherally-acting kappa agonist for visceral pain, and a dual-receptor agonist/antagonist molecule for neuropathic pain, both of which were created using the company's advanced polymer conjugate discovery platform. In addition, new preclinical data will be discussed for NKTR-214, Nektar's cancer immunotherapy candidate.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News